EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH

1 entry found
1
Conference item icon
Conference item

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

  • Morgensztern, D, Ong, TJ, Dols, MC, et al.
  • 2017-09-18
File available icon
Peer reviewed icon
Link to publisher copy available icon
FILTER RESULTS

TO TOP